![]() |
市場調查報告書
商品編碼
2026791
質子治療系統市場預測至2034年-按產品類型、類別、安裝配置、適應症、最終用戶和地區分類的全球分析Proton Therapy Systems Market Forecasts to 2034 - Global Analysis By Product Type, Type, Set-Up, Indication, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球質子治療系統市場規模將達到 10 億美元,並在預測期內以 7.0% 的複合年成長率成長,到 2034 年將達到 18 億美元。
質子束治療系統是一種先進的醫療技術,旨在提高癌症治療的精準度,進而改善治療效果,提升癌症患者的生活品質。質子束治療能夠根據腫瘤形狀進行精確的劑量匹配,在保護健康組織的同時,向癌細胞輸送更高劑量的輻射。
根據世界衛生組織(WHO)的數據,癌症是全球主要死因之一,2020 年約有 1,000 萬人死於癌症。
癌症發生率增加
質子束療法作為一種先進的放射療法,在癌症治療上具有許多優勢。它利用質子束精準靶向腫瘤,在最大限度減少對周圍健康組織損傷的同時,輸送更高劑量的輻射。這種標靶治療方式降低了傳統放射療法常見的副作用和長期併發症的風險。由於能夠實現精準的輻射輸送,質子束療法被公認為一種極具價值的治療方法,且市場需求日益成長。
使用限制
質子治療是一種先進且有效的治療方法,但與傳統放射治療設施相比,質子治療中心的數量和可近性有限。質子治療中心的地理分佈是限制其可近性的因素。此外,居住在偏遠或農村地區的患者由於路途遙遠且附近缺乏醫療設施,在接受質子治療方面可能面臨許多挑戰。因此,可近性的限制是阻礙市場擴張的主要因素。
技術進步
除了質子治療設備設計和功能的改進外,先進的治療計劃系統使醫務人員能夠進行高度精準的放射治療。先進成像技術的整合實現了腫瘤及其周圍健康組織的即時可視化,從而提高了治療的精確度。此外,治療計劃軟體的創新實現了個人化和自適應的治療方案,最佳化質子治療以滿足每位患者的個別需求。因此,這些技術創新正在加速市場成長。
替代技術的傳播
質子束療法雖然具有自身優勢,但強度調控放射治療(IMRT)和立體定位放射治療(SBRT)等替代技術已取得顯著進展,並在某些情況下達到與之相當的治療效果。 IMRT 是一種廣泛應用的放射治療技術,它利用多束放射線精確照射腫瘤,同時最大限度地減少對周圍健康組織的損傷。替代技術的廣泛應用對市場擴張構成了挑戰。
新冠疫情的感染疾病
質子治療系統市場受到新冠肺炎疫情的顯著影響。疫情期間醫療預算緊張,影響了投資決策,並可能延緩質子治療系統的部署。然而,新冠肺炎疫情也促進了創新與改變。遠端醫療解決方案擴大用於患者諮詢和後續觀察。人們對質子治療優勢(例如副作用較少)的認知不斷提高,凸顯了這種先進癌症治療方法的重要性。
在預測期內,旋轉質子治療系統細分市場預計將佔據最大佔有率。
旋轉式質子治療系統預計將佔據最大的市場佔有率。旋轉式質子治療系統採用可圍繞患者旋轉的機架,提供3D立體治療方案,從多個角度照射腫瘤。這種動態旋轉能夠更精準地靶向癌細胞,同時最大限度地減少對健康組織的損傷。此外,從多個方向進行質子束照射的能力提高了對腫瘤形狀的適應性,使其對形狀複雜不規則的腫瘤特別有效。
預計在預測期內,束流輻照系統細分市場將呈現最高的複合年成長率。
預計在預測期內,束流照射系統領域將實現顯著成長。這些系統負責將質子加速器的高能量質子束照射並控制到患者體內的腫瘤部位。質子束的穿透深度和強度透過能量調製器、磁鐵和準直器等組件的組合進行調整和控制。此外,最新的束流輸送系統通常採用掃描和點掃描技術,透過逐點照射質子束,實現更高的精度。
在預測期內,北美佔據了最大的市場佔有率。癌症發生率的上升,以及人們對質子治療益處的認知不斷提高,正在推動這些先進系統的應用。在美國,許多知名的癌症治療中心和研究機構營造了創新和技術應用的氛圍,加速了質子治療解決方案的開發和部署。此外,學術機構、醫療機構和產業相關人員之間的合作也促進了質子治療研究的進步和最佳實踐的傳播。
預計歐洲在預測期內將實現盈利成長。德國、法國和英國等歐洲國家對質子治療系統的需求強勁,這主要受癌症發生率上升和對創新醫療技術日益重視的推動。此外,該地區擁有眾多領先的癌症治療中心和研究機構,它們積極致力於先進質子治療解決方案的研發和應用。
According to Stratistics MRC, the Global Proton Therapy Systems Market is accounted for $1.0 billion in 2026 and is expected to reach $1.8 billion by 2034 growing at a CAGR of 7.0% during the forecast period. Proton therapy systems are advanced medical technologies designed for precise cancer treatment, offering enhanced therapeutic effectiveness and an improved quality of life for cancer patients. Proton therapy allows for precise dose conformity to the shape of the tumor, enabling higher radiation doses to be delivered to the cancer cells while sparing healthy tissues.
According to the WHO (World Health Organization), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.
Rising incidence of cancer
Proton therapy, as an advanced form of radiation therapy, offers several advantages in cancer treatment. It utilizes protons to precisely target tumours, delivering higher radiation doses while minimizing damage to surrounding healthy tissues. This targeted approach reduces the risk of side effects and long-term complications associated with conventional radiation therapy. Proton therapy, with its ability to provide precise and accurate radiation delivery, has gained recognition as a valuable treatment modality, which enhances market demand.
Limited accessibility
While proton therapy is an advanced and effective treatment modality, the availability and accessibility of proton therapy centers are limited compared to conventional radiation therapy facilities. The geographical distribution of proton therapy centers plays a role in limited accessibility. Moreover, patients residing in remote or rural areas may face significant challenges in accessing proton therapy due to the distance and lack of nearby facilities. Therefore, limited accessibility is a significant factor hampering market expansion.
Technological advancements
Improved design and functionality of proton therapy machines, coupled with sophisticated treatment planning systems, enable healthcare providers to deliver highly targeted radiation doses. The integration of advanced imaging technologies enhances the accuracy of treatment delivery by providing real-time visualization of the tumor and surrounding healthy tissues. Furthermore, software innovations in treatment planning facilitate personalized and adaptive approaches, optimizing proton therapy for individual patient needs. Hence, these technological innovations accelerate market growth.
Availability of alternative technologies
While proton therapy offers unique advantages, alternative technologies such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) have also advanced significantly, providing comparable treatment outcomes in certain cases. IMRT, a widely adopted radiation therapy technique, uses multiple beams of radiation that can be adjusted to deliver precise doses to the tumor while minimizing exposure to surrounding healthy tissues. The availability of alternative technologies poses a challenge to market expansion.
Covid-19 Impact
The proton therapy systems market has experienced significant impacts from the COVID-19 pandemic. The financial strain on healthcare budgets during the pandemic has influenced investment decisions, potentially slowing down the adoption of proton therapy systems. However, the pandemic has also prompted innovation and adaptation. Telehealth solutions have been increasingly employed for patient consultations and follow-ups. Awareness of the benefits of proton therapy, such as reduced treatment-related side effects, has grown, emphasizing the importance of advanced cancer treatment modalities.
The rotating proton therapy systems segment is expected to be the largest during the forecast period
The rotating proton therapy systems segment is estimated to hold the largest share. Rotating proton therapy systems utilize a gantry that can rotate around the patient, providing a three-dimensional approach to irradiating tumours from various angles. This dynamic rotation allows for more precise targeting of cancerous cells while minimizing exposure to healthy tissues. Moreover, the ability to deliver proton beams from multiple directions enables improved conformity to the shape of the tumor, making it particularly effective for complex and irregularly shaped tumours.
The beam delivery system segment is expected to have the highest CAGR during the forecast period
The beam delivery system segment is anticipated to have lucrative growth during the forecast period. This system is responsible for directing and controlling the delivery of high-energy proton beams from the proton accelerator to the tumor site within the patient's body. The proton beam's depth and intensity are shaped and modulated by a combination of components, such as energy modulation devices, magnets, and collimators. Furthermore, modern beam delivery systems often incorporate scanning or spot-scanning techniques, allowing for even greater precision by delivering proton beams spot by spot.
North America commanded the largest market share during the extrapolated period. The increasing incidence of cancer, coupled with a growing awareness of the benefits of proton therapy, drives the adoption of these advanced systems. In the United States, the presence of renowned cancer treatment centers and research institutions fosters a climate of innovation and technology adoption, propelling the development and deployment of proton therapy solutions. Additionally, collaborations between academic institutions, healthcare organizations, and industry players contribute to research advancements and the dissemination of best practices in proton therapy.
Europe is expected to witness profitable growth over the projection period. European countries, including Germany, France, the United Kingdom, and others, exhibit a strong demand for proton therapy systems, driven by a rising incidence of cancer and an increasing emphasis on innovative medical technologies. Moreover, the region boasts a network of leading cancer treatment centers and research institutions actively engaged in the development and application of advanced proton therapy solutions.
Key players in the market
Some of the key players in the Proton Therapy Systems Market include Mitsubishi Electric Corporation, Mevion Medical Systems, Hitachi, Advanced Oncotherapy plc, Ion Beam Applications SA, IBA worldwide, Varian, Provision Healthcare and ProTom International.
In April 2023, Mitsubishi Electric India CNC has announced partnership with SolidCAM, a global leader in innovative CAM software for CNC machines and distribution of related digital manufacturing solutions.
In August 2022, IBA, the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, announces it has signed a collaboration agreement with Apollo Hospitals Enterprise Ltd, to provide proton therapy training and education programs for IBA customers in Asia.